Exicure Inc XCUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XCUR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.60
- Day Range
- $0.57–0.61
- 52-Week Range
- $0.36–1.50
- Bid/Ask
- $0.57 / $0.60
- Market Cap
- $5.01 Mil
- Volume/Avg
- 23,891 / 246,368
Key Statistics
- Price/Earnings (Normalized)
- 0.32
- Price/Sales
- 0.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
- Website
- https://www.exicuretx.com
Valuation
|
Metric
|
XCUR
|
|---|---|
Price/Earnings (Normalized) | 0.32 |
Price/Book Value | 0.52 |
Price/Sales | 0.15 |
Price/Cash Flow | 0.53 |
Price/Earnings
XCUR
Financial Strength
|
Metric
|
XCUR
|
|---|---|
Quick Ratio | 1.63 |
Current Ratio | 2.56 |
Interest Coverage | — |
Quick Ratio
XCUR
Profitability
|
Metric
|
XCUR
|
|---|---|
Return on Assets (Normalized) | 18.16% |
Return on Equity (Normalized) | 64.67% |
Return on Invested Capital (Normalized) | 31.60% |
Return on Assets
XCUR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sznfhptgqk | Wpjzy | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nnhckykt | Cxfbx | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jjzxqflm | Kvctdk | $98.1 Bil | |
MRNA
| Moderna Inc | Kwvbpzxh | Yhdf | $39.1 Bil | |
ARGX
| argenx SE ADR | Zbrltnnx | Vsnjt | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Knwnqsst | Qyj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xnmzvlx | Lwbjp | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jwrpjcz | Jxntltn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rspzsypjqv | Ptfvqy | $12.5 Bil | |
INCY
| Incyte Corp | Tfzfzvqhn | Xnrnsk | $11.9 Bil |